DelveInsight’s “Coccidioidomycosis Pipeline Insight 2023” report provides comprehensive insights about key companies and pipeline drugs in the Coccidioidomycosis pipeline landscapes.
The report comprises Coccidioidomycosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Coccidioidomycosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Coccidioidomycosis pipeline products.
Coccidioidomycosis Overview
Coccidioidomycosis (also known as Valley Fever) is an infection usually caused by inhaling the spores (“seeds”) of either Coccidioides immitis or Coccidioides posadasii fungi. These spores are found in the soil in certain geographic areas (called endemic) and get into the air when the soil is disturbed. Coccidioidomycosis cannot be passed from person-to-person.
There are three forms of Coccidioidomycosis i.e. acute pulmonary coccidioidomycosis, chronic pulmonary coccidioidomycosis, and disseminated coccidioidomycosis. Disseminated coccidioidomycosis, is the most severe form of the disease and occurs in about 1% of all cases, usually in people who have a poor immune system or pregnant women. This form can spread to the nervous system, bones, joints or skin.
Some of the key takeaways from the Coccidioidomycosis Pipeline Report:
- Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Scynexis, Mycovia Pharmaceuticals, F2G, Amplyx Pharmaceuticals, etc., are developing therapies for the treatment of Coccidioidomycosis.
- Emerging therapies such as Ibrexafungerp, VT-1598, Fosmanogepix, Olorofim, are expected to have a significant impact on the Coccidioidomycosis market in the coming years.
Get an overview of pipeline landscape @ Coccidioidomycosis Clinical Trials Analysis
Coccidioidomycosis Pipeline Therapies along with Key Players:
- Ibrexafungerp: Scynexis
- VT-1598: Mycovia Pharmaceuticals
- Fosmanogepix: Amplyx Pharmaceuticals
- Olorofim: F2G
Scope of Coccidioidomycosis Pipeline Drug Insight
- Coverage: Global
- Major Players: Scynexis, Mycovia Pharmaceuticals, F2G, Amplyx Pharmaceuticals,and others.
- Pipeline Therapies: Ibrexafungerp, VT-1598, Fosmanogepix, Olorofim, and others.
Table of Contents
|
1 |
Coccidioidomycosis Report Introduction |
|
2 |
Coccidioidomycosis Executive Summary |
|
3 |
Coccidioidomycosis Overview |
|
4 |
Coccidioidomycosis- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Coccidioidomycosis Pipeline Therapeutics |
|
6 |
Coccidioidomycosis Late Stage Products (Phase II/III) |
|
7 |
Coccidioidomycosis Mid Stage Products (Phase II) |
|
8 |
Coccidioidomycosis Early Stage Products (Phase I) |
|
9 |
Coccidioidomycosis Preclinical Stage Products |
|
10 |
Coccidioidomycosis Therapeutics Assessment |
|
11 |
Coccidioidomycosis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Coccidioidomycosis Key Companies |
|
14 |
Coccidioidomycosis Key Products |
|
15 |
Coccidioidomycosis Unmet Needs |
|
16 |
Coccidioidomycosis Market Drivers and Barriers |
|
17 |
Coccidioidomycosis Future Perspectives and Conclusion |
|
18 |
Coccidioidomycosis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
Coccidioidomycosis Market
DelveInsight’s ‘Coccidioidomycosis-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Coccidioidomycosis Epidemiology
DelveInsight’s ‘Coccidioidomycosis Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/